Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This will be a semi-experimental study on constipation predominant IBS patient. One group of
patient will receive prucalopride 2mg daily and another group of patient will receive
lubiprostone 8 microgram twice daily. IBS-SSS and IBS-QOL score will be recorded at baseline
and at follow up at 3 week and 6 week. Effectiveness of both drug will be evaluated by
comparing the baseline data with data at 3 week and 6 week(IBS-SSS and IBS-QOL).
Phase:
Phase 4
Details
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh